Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Piper Sandler downgraded Luminex from Overweight to Neutral and set a new price target of $37.00 from $38.00 previously
BTIG downgraded Luminex from Buy to Neutral
4 - LUMINEX CORP (0001033905) (Issuer)
4 - LUMINEX CORP (0001033905) (Issuer)
4 - LUMINEX CORP (0001033905) (Issuer)
NEW YORK, July 12, 2021 /PRNewswire/ -- Middlesex Water Co. (NASD: MSEX) will replace Luminex Corp. (NASD: LMNX) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, July 15. DiaSorin S.p.A. is acquiring Luminex in a deal expected to be completed soon pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 15, 2021 S&P SmallCap 600 Addition Middlesex Water MSEX Utilities S&P SmallCap 600 Deletion Luminex LMNX Health Care For more information about S&P Dow Jones Indices, please visit www.spdji.com. ABOUT
AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the close of business June 17, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical
SALUGGIA, Italy, April 11, 2021 /PRNewswire/ -- DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation ((", Luminex", , NASDAQ:LMNX) for a price of USD 37.00 per share in an all-cash transaction. This corresponds to a total equity value of approximately USD 1.8 billion on a fully diluted basis and an enterprise value of approximately USD 1.8 billion. The cash consideration represents a c.23.1% premium to Luminex shareholders based on the unaffected closing stock price of Luminex on 24 February 2021 (the date prior to press rumors regarding a potentia
15-12G - LUMINEX CORP (0001033905) (Filer)
S-8 POS - LUMINEX CORP (0001033905) (Filer)
S-8 POS - LUMINEX CORP (0001033905) (Filer)
SC 13G/A - LUMINEX CORP (0001033905) (Subject)
SC 13G/A - LUMINEX CORP (0001033905) (Subject)
AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the close of business June 17, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq: LMNX) today announced results for its fourth quarter and full-year ended December 31, 2020. All amounts in this release are in conformity with U.S. generally accepted accounting principles ("GAAP"). CURRENT FINANCIAL HIGHLIGHTS Record revenue for the fourth quarter of $111.4M, a 23% increase over Q4 2019, and record revenue for the year of $417.4M, up 25% vs. 2019, driven primarily by growth associated with the COVID-19 global pandemic Gross margins of 58% for the quarter and 59% for the full year, an improvement of 3 and 4 percentage points, respectively, vs. Q4 and full-year 2019 Operating margin of $10.5M or 9
AUSTIN, Texas, Feb. 8, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the first quarter of 2021 of $0.10 per share of common stock payable on April 15, 2021 to stockholders of record as of the close of business March 25, 2021. About Luminex CorporationAt Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health. We offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, biodefense research, and food safety. We a